Eliya Levinger, Nir Gomel, Ami Hirsh, Maya Tenne, Asaf Achiron, Nadav Levinger, Shmuel Levinger, Nadav Shemesh, Adi Abulafia, Michael Mimouni, Nir Sorkin
{"title":"术前尼泊那克对酒精辅助光屈光性角膜切除术后疼痛和不适的附加作用。","authors":"Eliya Levinger, Nir Gomel, Ami Hirsh, Maya Tenne, Asaf Achiron, Nadav Levinger, Shmuel Levinger, Nadav Shemesh, Adi Abulafia, Michael Mimouni, Nir Sorkin","doi":"10.1177/25158414251349340","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the effect of preoperative nepafenac on pain following alcohol-assisted photorefractive keratectomy (PRK).</p><p><strong>Settings: </strong>Tel-Aviv Sourasky Medical Center-a tertiary medical center.</p><p><strong>Design: </strong>Observational case-series.</p><p><strong>Methods: </strong><i>Setting</i>: Refractive center. <i>Study Population</i>: 205 PRK patients grouped randomly into five according to pain-management protocols: (1) paracetamol/ibuprofen (Parac-Ibupr group, <i>n</i> = 39), (2) high-dose oxycodone/naloxone only (Oxy-only group, <i>n</i> = 45), (3) oxycodone/naloxone and postoperative 0.1%-nepafenac (Oxy-Nep group, <i>n</i> = 36), (4) oxycodone/naloxone and preoperative and postoperative 0.1%-nepafenac (Nep-Oxy-Nep group, <i>n</i> = 42), and (5) preoperative and postoperative 0.1%-nepafenac only (Nep-only group, <i>n</i> = 43). Preoperative nepafenac was administered three times daily for 2 days. <i>Main Outcome Measures</i>: Mean and maximal pain levels (postop days 1-5), duration of tearing/photophobia, number of pain tablets taken, uncorrected visual acuity (UCVA), side effects and epithelial healing delay.</p><p><strong>Results: </strong>Mean pain scores differed significantly between groups (<i>p</i> < 0.001)-lowest in groups receiving preop nepafenac (Nep-only: 1.8 ± 1.6, Nep-Oxy-Nep: 2.3 ± 1.5) compared to the Oxy-Nep (3.2 ± 1.9), Oxy-only (3.8 ± 1.7), and Parac-Ibupr (4.8 ± 1.6) groups. Similar findings were observed with maximal pain scores. Total number of pain tablets taken was lowest in the Nep-only group. Duration of photophobia was shortest in groups receiving preoperative nepafenac (<i>p</i> < 0.001). Duration of tearing was longest in the Parac-Ibupr group (<i>p</i> < 0.001). Nausea/vomiting occurred in 20% of the Oxy-only group (<i>p</i> < 0.001). There were four cases of delayed epithelial healing-all in groups not treated with nepafenac. One-month UCVA did not differ between groups. No additional independent factors were found to be associated with pain except age.</p><p><strong>Conclusion: </strong>Adding preoperative nepafenac significantly reduced pain and photophobia with complete epithelial healing. Addition of oral opiates to nepafenac treatment had little analgetic benefit.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251349340"},"PeriodicalIF":2.3000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188066/pdf/","citationCount":"0","resultStr":"{\"title\":\"The added effect of preoperative nepafenac on pain and discomfort following alcohol-assisted photorefractive keratectomy.\",\"authors\":\"Eliya Levinger, Nir Gomel, Ami Hirsh, Maya Tenne, Asaf Achiron, Nadav Levinger, Shmuel Levinger, Nadav Shemesh, Adi Abulafia, Michael Mimouni, Nir Sorkin\",\"doi\":\"10.1177/25158414251349340\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To evaluate the effect of preoperative nepafenac on pain following alcohol-assisted photorefractive keratectomy (PRK).</p><p><strong>Settings: </strong>Tel-Aviv Sourasky Medical Center-a tertiary medical center.</p><p><strong>Design: </strong>Observational case-series.</p><p><strong>Methods: </strong><i>Setting</i>: Refractive center. <i>Study Population</i>: 205 PRK patients grouped randomly into five according to pain-management protocols: (1) paracetamol/ibuprofen (Parac-Ibupr group, <i>n</i> = 39), (2) high-dose oxycodone/naloxone only (Oxy-only group, <i>n</i> = 45), (3) oxycodone/naloxone and postoperative 0.1%-nepafenac (Oxy-Nep group, <i>n</i> = 36), (4) oxycodone/naloxone and preoperative and postoperative 0.1%-nepafenac (Nep-Oxy-Nep group, <i>n</i> = 42), and (5) preoperative and postoperative 0.1%-nepafenac only (Nep-only group, <i>n</i> = 43). Preoperative nepafenac was administered three times daily for 2 days. <i>Main Outcome Measures</i>: Mean and maximal pain levels (postop days 1-5), duration of tearing/photophobia, number of pain tablets taken, uncorrected visual acuity (UCVA), side effects and epithelial healing delay.</p><p><strong>Results: </strong>Mean pain scores differed significantly between groups (<i>p</i> < 0.001)-lowest in groups receiving preop nepafenac (Nep-only: 1.8 ± 1.6, Nep-Oxy-Nep: 2.3 ± 1.5) compared to the Oxy-Nep (3.2 ± 1.9), Oxy-only (3.8 ± 1.7), and Parac-Ibupr (4.8 ± 1.6) groups. Similar findings were observed with maximal pain scores. Total number of pain tablets taken was lowest in the Nep-only group. Duration of photophobia was shortest in groups receiving preoperative nepafenac (<i>p</i> < 0.001). Duration of tearing was longest in the Parac-Ibupr group (<i>p</i> < 0.001). Nausea/vomiting occurred in 20% of the Oxy-only group (<i>p</i> < 0.001). There were four cases of delayed epithelial healing-all in groups not treated with nepafenac. One-month UCVA did not differ between groups. No additional independent factors were found to be associated with pain except age.</p><p><strong>Conclusion: </strong>Adding preoperative nepafenac significantly reduced pain and photophobia with complete epithelial healing. Addition of oral opiates to nepafenac treatment had little analgetic benefit.</p>\",\"PeriodicalId\":23054,\"journal\":{\"name\":\"Therapeutic Advances in Ophthalmology\",\"volume\":\"17 \",\"pages\":\"25158414251349340\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-06-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188066/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Ophthalmology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/25158414251349340\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25158414251349340","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:评价术前应用neafenac对酒精辅助光屈光性角膜切除术(PRK)术后疼痛的影响。环境:特拉维夫苏拉斯基医疗中心-三级医疗中心。设计:观察性病例系列。方法:设置:屈光中心。研究人群:205例PRK患者根据疼痛管理方案随机分为5组:(1)扑热息痛/布洛芬(扑热息痛-布洛芬组,n = 39),(2)大剂量氧可酮/纳洛酮联合术后0.1%- neafenac(氧-nep组,n = 36),(4)氧可酮/纳洛酮联合术前术后0.1%- neafenac (nep -氧-nep组,n = 42),(5)术前术后0.1%- neafenac (nep -nep组,n = 43)。术前给予neafenac,每日3次,连用2天。主要观察指标:平均和最大疼痛水平(术后1-5天)、撕裂/畏光持续时间、服用止痛片数量、未矫正视力(UCVA)、副作用和上皮愈合延迟。结果:两组间疼痛评分差异有统计学意义(p p p p p)。结论:术前加入neafenac可显著减轻疼痛和畏光,上皮细胞完全愈合。口服阿片类药物加入尼帕尼酸治疗几乎没有镇痛效果。
The added effect of preoperative nepafenac on pain and discomfort following alcohol-assisted photorefractive keratectomy.
Purpose: To evaluate the effect of preoperative nepafenac on pain following alcohol-assisted photorefractive keratectomy (PRK).
Settings: Tel-Aviv Sourasky Medical Center-a tertiary medical center.
Design: Observational case-series.
Methods: Setting: Refractive center. Study Population: 205 PRK patients grouped randomly into five according to pain-management protocols: (1) paracetamol/ibuprofen (Parac-Ibupr group, n = 39), (2) high-dose oxycodone/naloxone only (Oxy-only group, n = 45), (3) oxycodone/naloxone and postoperative 0.1%-nepafenac (Oxy-Nep group, n = 36), (4) oxycodone/naloxone and preoperative and postoperative 0.1%-nepafenac (Nep-Oxy-Nep group, n = 42), and (5) preoperative and postoperative 0.1%-nepafenac only (Nep-only group, n = 43). Preoperative nepafenac was administered three times daily for 2 days. Main Outcome Measures: Mean and maximal pain levels (postop days 1-5), duration of tearing/photophobia, number of pain tablets taken, uncorrected visual acuity (UCVA), side effects and epithelial healing delay.
Results: Mean pain scores differed significantly between groups (p < 0.001)-lowest in groups receiving preop nepafenac (Nep-only: 1.8 ± 1.6, Nep-Oxy-Nep: 2.3 ± 1.5) compared to the Oxy-Nep (3.2 ± 1.9), Oxy-only (3.8 ± 1.7), and Parac-Ibupr (4.8 ± 1.6) groups. Similar findings were observed with maximal pain scores. Total number of pain tablets taken was lowest in the Nep-only group. Duration of photophobia was shortest in groups receiving preoperative nepafenac (p < 0.001). Duration of tearing was longest in the Parac-Ibupr group (p < 0.001). Nausea/vomiting occurred in 20% of the Oxy-only group (p < 0.001). There were four cases of delayed epithelial healing-all in groups not treated with nepafenac. One-month UCVA did not differ between groups. No additional independent factors were found to be associated with pain except age.
Conclusion: Adding preoperative nepafenac significantly reduced pain and photophobia with complete epithelial healing. Addition of oral opiates to nepafenac treatment had little analgetic benefit.